title: Discriminative stimulus effects of gamma-hydroxybutyrate: role of training dose.
abstract: gamma-Hydroxybutyrate (GHB) is a drug of abuse with actions at GHB and GABA receptors. This study examined whether the relative importance of GABA(A), GABA(B), and GHB receptors in the discriminative stimulus effects of GHB depends on the training dose. In comparison with a previous 100 mg/kg GHB-saline discrimination, pigeons were trained to discriminate either 178 or 56 mg/kg GHB from saline. Increasing the training dose shifted the GHB gradient to the right, and decreasing it shifted the gradient to the left. Similar shifts occurred with the GHB precursor gamma-butyrolactone, which substituted for GHB, and with the GABA(B) agonists baclofen and 3-aminopropyl(methyl)phosphinic acid hydrochloride (SKF97541) and the benzodiazepine diazepam, each of which produced at most 54 to 68% GHB-appropriate responding. The benzodiazepine antagonist flumazenil, the benzodiazepine inverse agonist ethyl 8-azido-6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-alpha]-[1,4]-benzodiazepine-3-carboxylate (Ro 15-4513), and the GHB receptor antagonist (2E)-5-hydroxy-5,7,8,9-tetrahydro-6H-benzo[a][7]annulen-6-ylidene ethanoic acid (NCS-382) produced a maximum of 66 to 97% GHB-appropriate responding in animals discriminating 56 or 100 mg/kg GHB and a maximum of 1 to 49% in animals discriminating 178 mg/kg. NCS-382 did not attenuate the effects of GHB. The GABA(B) antagonist 3-aminopropyl(diethoxymethyl)phosphinic acid (CGP35348) blocked GHB at all training doses. The results suggest that increasing the training dose of GHB increases the pharmacological selectivity of its discriminative stimulus effects. At a high training dose, diazepam-insensitive GABA(A) receptors, for which flumazenil and Ro 15-4513 have affinity, may no longer be involved. Diazepam-sensitive GABA(A) receptors and GABA(B) receptors appear to play a similar role at all training doses. There was no evidence for GHB receptor involvement.
authors.affiliation: Department of Psychiatry and Pharmacology, University of Texas Health Science Center at San Antonio, 78229-3900, USA. koek@uthscsa.edu
authors.forename: Wouter
authors.initials: W
authors.lastname: Koek
authors.forename: Weibin
authors.initials: W
authors.lastname: Chen
authors.forename: Susan L
authors.initials: SL
authors.lastname: Mercer
authors.forename: Andrew
authors.initials: A
authors.lastname: Coop
authors.forename: Charles P
authors.initials: CP
authors.lastname: France
mesh_terms: D000818:Animals; D010856:Columbidae; D003216:Conditioning, Operant / Q000187:drug effects; D004192:Discrimination, Psychological / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D018755:GABA Agonists / Q000494:pharmacology; D018756:GABA Antagonists / Q000494:pharmacology; D011956:Receptors, Cell Surface / Q000378:metabolism*; D011963:Receptors, GABA-A / Q000378:metabolism*; D018080:Receptors, GABA-B / Q000378:metabolism*; D012978:Sodium Oxybate / Q000008:administration & dosage* / Q000494:pharmacology*
chemical_list: C039403:4-hydroxybutyric acid receptor; D018755:GABA Agonists; D018756:GABA Antagonists; D011956:Receptors, Cell Surface; D011963:Receptors, GABA-A; D018080:Receptors, GABA-B; D012978:Sodium Oxybate